Pfizer Says ELREXFIO Meets Primary Endpoint in Phase 3 Study
Pfizer announced topline results from the Phase 3 MagnetisMM-32 study of ELREXFIO in adults with relapsed or refractory multiple myeloma.
Story updates
10:45:30 AM UTC
SquawkNews
PFIZER - PLANS GLOBAL HEALTH AUTHORITY SUBMISSIONS AND FUTURE PUBLICATION OF MAGNETISMM-32 RESULTS
11:34:32 AM UTC
SquawkNews
Pfizer Inc. NYSE:PFE
Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatux…